|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Top Lists |
Insider Trading Graph View |
Insider Watch |
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise" - Peter Lynch ==>> What is insider trading>> |

| Transaction & Date | Reported Date |
Company | Symbol | Insider Relationship |
Shares Traded | Average Price | Total Amount |
Shares Ownership |
Filing |
| 2006-09-13 Sale |
2006-09-15 6:12 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 37,500 | $20 | $750,000 | 32,171 (Direct) | View |
| 2006-03-17 Sale |
2006-03-21 12:07 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 25,000 | $15 | $375,000 | 24,355 (Direct) |
View |
| 2003-12-01 Sale |
2003-12-02 4:41 pm |
LUMINEX CORP | LMNX | MARTIN RANDEL S (VP, Marketing/Sales) | 20,400 | $10.16 | $207,248 | 0 (Direct) |
View |
| Transaction & Date | Reported Date | Company | Symbol | Insider Relationship |
Shares Traded | Average Price |
Total Amount | Shares Ownership | Filing |
| 2007-04-05 Tax Withholding | 2007-04-11 2:33 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 548 | $14.09 | $7,721 | 38,300 (Direct) |
View |
| 2007-03-31 Tax Withholding |
2007-04-03 6:51 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 1,140 | $13.72 | $15,641 | 38,848 (Direct) | View |
| 2007-03-25 Option Award | 2007-03-27 7:53 pm |
LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 7,817 | $0 | $0 | 39,988 (Direct) | View |
| 2006-09-13 Exercise | 2006-09-15 6:12 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 37,500 | $4.68 | $175,500 | 69,671 (Direct) | View |
| 2006-03-25- -2006-04-05 Option Award Tax Withholding | 2006-04-07 2:26 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 10,832 | $2.05 | $22,210 | 32,171 (Direct) |
View |
| 2006-03-17 Exercise | 2006-03-21 12:07 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 25,000 | $6.52 | $163,000 | 49,355 (Direct) |
View |
| 2005-03-31 Option Award | 2005-04-04 4:58 pm | LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Marketing/Sales & Bus Dev) | 19,355 | $0 | $0 | 24,355 (Direct) |
View |
| 2004-03-25 Option Award |
2004-03-29 8:27 pm | LUMINEX CORP | LMNX | MARTIN RANDEL S (VP, Marketing/Sales & Bus Dev) | 5,000 | $0 | $0 | 5,000 (Direct) |
View |
| 2003-12-01 Exercise |
2003-12-02 4:41 pm |
LUMINEX CORP | LMNX | MARTIN RANDEL S (VP, Marketing/Sales) | 20,400 | $3.92 | $79,968 | 20,400 (Direct) |
View |
| Transaction & Date |
Reported Date | Exercisable Expiration | Company | Symbol | Insider Relationship | Shares Traded |
Conversion Price | Shares Ownership |
Filing |
| 2007-03-25 Option Award |
2007-03-27 7:53 pm | N/A 2017-03-25 |
LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 5,211 | $14.39 | 5,211 (Direct) | View |
| 2006-09-13 Exercise |
2006-09-15 6:12 pm | 2004-03-17 2013-03-17 |
LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 37,500 | $4.68 | 0 (Direct) | View |
| 2006-03-17 Exercise | 2006-03-21 12:07 pm |
2005-05-23 2012-05-23 |
LUMINEX CORP | LMNX | MARFIN RANDEL S (VP, Luminex Bioscience Group) | 25,000 | $6.52 | 0 (Direct) | View |
| 2004-03-25 Option Award |
2004-03-29 8:27 pm | N/A 2014-03-25 |
LUMINEX CORP | LMNX | MARTIN RANDEL S (VP, Marketing/Sales & Bus Dev) | 15,000 | $8.22 | 15,000 (Direct) |
View |
| 2003-12-01 Exercise |
2003-12-02 4:41 pm |
N/A 2004-05-20 |
LUMINEX CORP | LMNX | MARTIN RANDEL S (VP, Marketing/Sales) | 20,400 | $3.92 | 0 (Direct) | View |
|
© 2005-2008 SecForm4.Com All rights reserved. Archives: 2008 2007 2006 2005 2004 2003 Mon, 01 Dec 2008 17:43:08 -0600 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC. SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |